Drugs & Pharmacology This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory.

Involvement of Spinal CC Chemokine Ligand 5 in the Development of Bone Cancer Pain in Rats
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - June 20, 2013 Category: Drugs & Pharmacology Authors: Li‐Hua Hang, Dong‐Hua Shao, Zheng Chen, Yuan‐Feng Chen, Wei‐Wei Shu, Zhi‐Guo Zhao Tags: Original Article Source Type: research

Editorial Board
(Source: International Journal of Antimicrobial Agents)
Source: International Journal of Antimicrobial Agents - June 20, 2013 Category: Drugs & Pharmacology Source Type: research

Systematic review: worldwide variation in the frequency of coeliac disease and changes over time
ConclusionsCoeliac disease is increasing in frequency, with significant geographical differences. Although few cases have been described to date in the Orient and Sub‐Saharan Africa, there is a significant prevalence of HLA DQ2 and wheat consumption is of the same order as that in Western Europe. CD may therefore become more common in the future in these countries. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 20, 2013 Category: Drugs & Pharmacology Authors: J. Y. Kang, A. H. Y. Kang, A. Green, K. A. Gwee, K. Y. Ho Tags: Systematic Review Source Type: research

Proton Pump Inhibitor Therapy for Eosinophilic EsophagitisProton Pump Inhibitor Therapy for Eosinophilic Esophagitis
Are proton pump inhibitors the most effective way to treat eosinophilic esophagitis? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Jakavi® impacted an underlying mechanism of disease
Novartis has announced results from a Phase III three-year follow-up study that showed Jakavi® (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

RoActemra® shows long-term efficacy
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced data from two phase III studies using RoActemra in patients with rheumatoid arthritis (RA): the long-term extension (LTE) follow up of the AMBITION study demonstrated long-term efficacy of RoActemra without methotrexate (MTX); and the FUNCTION study showed the clinical benefits of the medicine, alone or in combination with MTX, when used to treat patients with early RA.(1,2) These studies are being presented at the 2013 European League Against Rheumatism (EULAR) Congress. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Two-year data from clinical trial of HUMIRA®
AbbVie (NYSE: ABBV) has announced two-year results from two post-hoc data analyses of the ongoing, open-label extension (OLE) portion of the Phase 3 ABILITY-1 trial. The ABILITY-1 trial is the first large, randomised, pivotal study evaluating the use of HUMIRA® (adalimumab) to treat patients with non-radiographic axial spondyloarthritis (nr-axSpA). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Revlimid® indicated as a treatment for patients with rare form of blood disease
Celgene International Sàrl (NASDAQ: CELG) has been notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

First guidelines for treating non-transfusion-dependent thalassaemia
New guidelines released by the Thalassaemia International Federation (TIF) address the Management of Non-Transfusion Dependent Thalassaemias (NTDT) and are a first of their kind in the field of medical haematology. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Milestone triggering payment to fund novel C. difficile antibiotic
Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infections (CDI), has announced that it has achieved a clinical research milestone in the development of its novel CDI antibiotic SMT 19969 triggering a £740,000 payment under the Company’s existing Translation Award from the Wellcome Trust. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

PRAC recommends suspending marketing authorisations for HE starches
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded following a review of the available evidence that the benefits of infusion solutions containing hydroxyethyl-starch (HES) no longer outweigh their risks and therefore recommended that the marketing authorisations for these medicines be suspended. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 19, 2013 Category: Drugs & Pharmacology Source Type: news

Protein Being Studied To Fight Cancer; May Cause Toxicity In Cardiac Cells
A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function. Their study, published in th journal Genes & Development, found that deletion of the gene encoding MCL-1 in adult mouse hearts led to rapid heart failure within two weeks, and death within a month. MCL-1 (myeloid cell leukemia-1) is an anti-apoptotic protein, meaning that it prevents or delays the death of a cell... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 19, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Synergistic Combination of Small Molecule Inhibitor and RNA Interference against Antiapoptotic Bcl-2 Protein in Head and Neck Cancer Cells
Molecular PharmaceuticsDOI: 10.1021/mp4001662 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 18, 2013 Category: Drugs & Pharmacology Authors: Yen-Ling Lin, Yasemin Yuksel Durmaz, Jacques E. Nör and Mohamed E. H. ElSayed Source Type: research

Eudragit E PO as a Complementary Material for Designing Oral Drug Delivery Systems with Controlled Release Properties: Comparative Evaluation of New Interpolyelectrolyte Complexes with Countercharged Eudragit L100 Copolymers
Molecular PharmaceuticsDOI: 10.1021/mp4000635 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 18, 2013 Category: Drugs & Pharmacology Authors: R. I. Moustafine, A. V. Bukhovets, A. Y. Sitenkov, V. A. Kemenova, P. Rombaut and G. Van den Mooter Source Type: research

Drug-Resistant Prostate Cancer Treated With New Medication In The Laboratory
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results were presented at The Endocrine Society's 95th Annual Meeting in San Francisco. "Our novel prostate cancer drug works by a unique mechanism of action," said study lead author Jeremy Jones, PhD, assistant professor of molecular pharmacology at City of Hope, Beckman Research Institute, in Duarte, CA. "Thus, it has the potential to treat cancers resistant to currently approved therapies... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 18, 2013 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Exploratory Study [Pharmacology]
Conclusions— In patients with non–ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention, ticagrelor augments CBFV to a greater extent than prasugrel when incremental doses of adenosine are administered. Although exploratory, these results may represent a pleiotropic action of ticagrelor, possibly contributing to its beneficial effects in such patients. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01642966 (Source: Circulation: Cardiovascular Interventions)
Source: Circulation: Cardiovascular Interventions - June 18, 2013 Category: Cardiology Authors: Alexopoulos, D., Moulias, A., Koutsogiannis, N., Xanthopoulou, I., Kakkavas, A., Mavronasiou, E., Davlouros, P., Hahalis, G. Tags: Platelet function inhibitors, Acute coronary syndromes, Antiplatelets Pharmacology Source Type: research

Inhibition of Late Sodium Current by Mexiletine: A Novel Pharmotherapeutical Approach in Timothy Syndrome [Original Articles]
Conclusions— Mexiletine shortened QTc, attenuated QT–RR slope, abolished 2:1 AV block and T wave alternans in a TS1 patient and TS model via inhibition of late INa. (Source: Circulation: Arrhythmia and Electrophysiology)
Source: Circulation: Arrhythmia and Electrophysiology - June 18, 2013 Category: Cardiology Authors: Gao, Y., Xue, X., Hu, D., Liu, W., Yuan, Y., Sun, H., Li, L., Timothy, K. W., Zhang, L., Li, C., Yan, G.-X. Tags: Cardiovascular Pharmacology, Arrythmias-basic studies, Ion channels/membrane transport, Genetics of cardiovascular disease Original Articles Source Type: research

Reporting on Adverse Clinical Events
(Source: Clin-Alert)
Source: Clin-Alert - June 18, 2013 Category: Drugs & Pharmacology Tags: Articles Source Type: research

Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid -- an analysis of Cambodian samples
Conclusions: Improper packaging and storage conditions may reduce the quality of amoxicillin--clavulanic acid preparations at community pharmacies. Strict quality control measures are urgently needed to maintain the quality of amoxicillin--clavulanic acid in tropical countries. (Source: BMC Clinical Pharmacology)
Source: BMC Clinical Pharmacology - June 18, 2013 Category: Drugs & Pharmacology Authors: Mohiuddin KhanKirara HatanakaTey SovannarithNam NivannaLidia CasasNaoko YoshidaHirohito TsuboiTsuyoshi TanimotoKazuko Kimura Source Type: research

Interview with John W. Kozarich, PhD
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 283-288. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

Positron Emission Tomography Imaging of Angiogenesis in a Murine Hindlimb Ischemia Model with 64Cu-Labeled TRC105
Molecular PharmaceuticsDOI: 10.1021/mp400191w (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 17, 2013 Category: Drugs & Pharmacology Authors: Hakan Orbay, Yin Zhang, Hao Hong, Timothy A. Hacker, Hector F. Valdovinos, James A. Zagzebski, Charles P. Theuer, Todd E. Barnhart and Weibo Cai Source Type: research

In Vitro and Ex Vivo Evaluation of Polymeric Nanoparticles for Vaginal and Rectal Delivery of the Anti-HIV Drug Dapivirine
Molecular PharmaceuticsDOI: 10.1021/mp4002365 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 17, 2013 Category: Drugs & Pharmacology Authors: José das Neves, Francisca Araújo, Fernanda Andrade, Johan Michiels, Kevin K. Ariën, Guido Vanham, Mansoor Amiji, Maria Fernanda Bahia and Bruno Sarmento Source Type: research

Nanobiotix receives approval from ANSM
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has announced that its lead compound NBTXR3 has received authorisation from the French Medicine Agency, ANSM,(1) to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment centre. This represents a second indication for NBTXR3 which is also in clinical trials for soft tissue sarcoma. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 17, 2013 Category: Drugs & Pharmacology Source Type: news

RAPID™-PsA study highlights burden of psoriatic arthritis
UCB has announced new data from the RAPIDTM-PsA study on certolizumab pegol in the treatment of moderate to severe psoriatic arthritis (PsA) at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 17, 2013 Category: Drugs & Pharmacology Source Type: news

Subcutaneously delivered contraceptive launched by Pfizer
Sayana® Press (medroxyprogesterone acetate), the first subcutaneously delivered long-acting reversible contraceptive (LARC) has been launched by Pfizer. It is administered by a doctor or nurse, given under the skin into the thigh or abdomen every 13 weeks using a prefilled Uniject injection. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 17, 2013 Category: Drugs & Pharmacology Source Type: news

Literature Search and Review
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 289-298. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block VEGF–KDR Binding Using Label-Free Microarray-Based Assays
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 326-332. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

Development of a High-Throughput Screen to Detect Inhibitors of TRPS1 Sumoylation
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 308-325. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

A High-Throughput Yeast Assay Identifies Synergistic Drug Combinations
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 299-307. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

PRIMOS: An Integrated Database of Reassessed Protein–Protein Interactions Providing Web-Based Access to In Silico Validation of Experimentally Derived Data
ASSAY and Drug Development Technologies Jun 2013, Vol. 11, No. 5: 333-346. (Source: ASSAY and Drug Development Technologies)
Source: ASSAY and Drug Development Technologies - June 17, 2013 Category: Drugs & Pharmacology Tags: article Source Type: research

Acetal Derivatives as Prodrugs of Resveratrol
Molecular PharmaceuticsDOI: 10.1021/mp400226p (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - June 17, 2013 Category: Drugs & Pharmacology Authors: Andrea Mattarei, Michele Azzolini, Massimo Carraro, Nicola Sassi, Mario Zoratti, Cristina Paradisi and Lucia Biasutto Source Type: research

Multi-stakeholder report myeloma treatment
Myeloma Patients Europe has announced the launch of a multi-stakeholder report on patient perspectives of myeloma treatment and care and their role in myeloma research. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 17, 2013 Category: Drugs & Pharmacology Source Type: news

PHARMACOL REV; +121 new citations
121 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: PHARMACOL REV These pubmed results were generated on 2013/06/17PubMed, a service of the National Library of Medicine, includes over 15 million citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals. PubMed includes links to many sites providing full text articles and other related resources. (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - June 17, 2013 Category: Drugs & Pharmacology Tags: Report Source Type: research

Lantus (Insulin Glargine [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 17, 2013 Category: Drugs & Pharmacology Source Type: news

Cav2.3 (R‐type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo
Summary PurposeLamotrigine (LTG) is a popular modern antiepileptic drug (AED); however, its mechanism of action has yet to be fully understood, as it is known to modulate many members of several ion channel families. In heterologous systems, LTG inhibits Cav2.3 (R‐type) calcium currents, which contribute to kainic‐acid (KA)–induced epilepsy in vivo. To gain insight into the role of R‐type currents in LTG drug action in vivo, we compared the effects of LTG to two other AEDs in Cav2.3‐deficient mice and controls on KA‐induced seizures. MethodsBehavioral seizure rating and quantitative electrocorticography were pe...
Source: Epilepsia - June 17, 2013 Category: Neurology Authors: Maxine Dibué, Marcel A. Kamp, Serdar Alpdogan, Etienne E. Tevoufouet, Wolfram F. Neiss, Jürgen Hescheler, Toni Schneider Tags: Full‐Length Original Research Source Type: research

Study identifies protein essential for normal heart function
(University of California - San Diego) A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2013 Category: Global & Universal Source Type: news

Commentary: revisiting the past – does it hold the key to the future treatment of refractory GERD?
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: P. O. Katz, F. Schnoll‐Sussman Tags: Invited Commentaries Source Type: research

Commentary: revisiting the past – does it hold the key to the future treatment of refractory GERD? Author's reply
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: M. Fox Tags: Invited Commentary Source Type: research

Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy – optimisation is the way forward
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: J. Molina‐Infante, J. P. Gisbert Tags: Invited Commentary Source Type: research

Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy – optimisation is the way forward; authors' reply
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: F. Sierra, J. D. Forero, M. Rey, M. L. Botero, A. Cárdenas Tags: Invited Commentary Source Type: research

Letter: mucosal healing in ulcerative colitis – higher relevance than in Crohn's disease?
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: M. Barreiro‐de Acosta, J. P. Gisbert Tags: Letters to the Editors Source Type: research

Letter: mucosal healing in ulcerative colitis – higher relevance than in Crohn's disease? Authors' reply
(Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - June 17, 2013 Category: Drugs & Pharmacology Authors: D. Laharie, J. Filippi, X. Roblin, S. Nancey, L. Peyrin‐Biroulet Tags: Letter to the Editor Source Type: research